Hormone-receptor-negative breast cancer—most of it triple-negative, meaning the tumor lacks estrogen receptors, progesterone receptors and surplus HER2—is among the most lethal common subtypes of the disease. It disproportionately strikes younger women and carriers of BRCA1 mutations, grows quickly, and metastasizes early. Once it reaches distant organs, survival is measured in a few years at best, and historically it was counted in months. Recent gains have been incremental at best. Platinum salts and taxanes remain the chemotherapy backbone, and pembrolizumab added to chemotherapy extends life chiefly in the minority of patients whose tumors express the PD-L1 protein at high levels—a biomarker found in fewer than half of metastatic cases. For everyone else, checkpoint inhibitors have offered little. Adding to the challenge, pathologists now recognize that a large share of these apparently HER2-negative tumors are not truly negative: they carry low levels of the HER2 protein on the cell surface, visible as faint immunohistochemical staining, a state the field has termed HER2-low.

HER2-low is defined as cancer scored 1+ on immunohistochemistry, or 2+ with no gene amplification on in situ hybridization—receptor levels once dismissed as biologically irrelevant. Trastuzumab deruxtecan, developed by Daiichi Sankyo and AstraZeneca, changed that view. The drug consists of a trastuzumab antibody tethered through an enzyme-cleavable tetrapeptide linker to deruxtecan, a potent inhibitor of topoisomerase I, an enzyme that dividing cells need to untangle DNA during replication. With roughly eight payload molecules riding on each antibody—a drug-to-antibody ratio far higher than earlier conjugates achieved—the drug delivers a concentrated chemotherapy dose directly to HER2-expressing cells. After the antibody binds its target and is engulfed into the lysosome, tumor-cell enzymes clip the linker, releasing the payload to poison DNA replication. Critically, the released drug is membrane-permeable, so it diffuses into neighboring tumor cells that express little or no HER2. This bystander effect explains why the conjugate works at receptor densities once considered far too low to target, and in earlier randomized studies it roughly doubled progression-free survival compared with standard chemotherapy in pretreated patients with HER2-low metastatic disease.

Durvalumab attacks the tumor from a different direction. The monoclonal antibody binds PD-L1, the molecular brake that tumors and immune cells deploy to shut down cytotoxic T lymphocytes, releasing those cells to resume their attack. The logic for combining it with trastuzumab deruxtecan rests on a decade of tumor immunology showing that antibody-drug conjugates do far more than kill their targets. The DNA damage inflicted by topoisomerase I inhibition can activate the cGAS–STING pathway, the cell’s alarm sensor for misplaced DNA, triggering type I interferon release. Dying tumor cells spill antigens that dendritic cells carry to lymph nodes for T-cell priming, while stressed tumor cells raise the density of MHC class I molecules and PD-L1 on their surface. In laboratory models, topoisomerase I inhibitors effectively behave as an in situ vaccine, converting immunologically cold tumors into inflamed ones that checkpoint inhibitors can exploit. The question BEGONIA posed was whether this mechanistic synergy would hold in human breast cancer, in women receiving both agents as their first treatment for advanced disease.

BEGONIA was conceived as a platform study rather than a single comparison: multiple parallel arms tested durvalumab alongside different investigational partners, including antibodies against CD73 and NKG2A, a STAT3-targeting antisense oligonucleotide, and trastuzumab deruxtecan. The design allowed several drug combinations to be evaluated simultaneously under shared infrastructure, with each arm reporting once it accrued enough patients. The arm reported in Nature Cancer enrolled women with locally advanced, unresectable or metastatic hormone-receptor-negative breast cancer whose tumors were HER2-low and who had not yet received drug therapy for advanced disease. Patients received both agents at established doses on three-week cycles, continuing until their disease progressed or toxicity became unacceptable. Because the study was open-label and lacked a randomized control group, its primary endpoint was the objective response rate—the proportion of patients whose tumors shrank by at least 30 percent, as confirmed by blinded independent central review—together with duration of response, progression-free survival and safety. Enrollment spanned cancer centers across Europe, Asia and North America, capturing the heterogeneity of real-world clinical populations.

The efficacy signals exceeded what either drug’s record alone would predict. Around 62 percent of patients achieved a confirmed objective response, and a small subset saw all detectable disease disappear—complete responses that are rare with conventional first-line chemotherapy in this setting. The median duration of response had not been reached when the data were locked, with the majority of responses still ongoing at analysis and many patients remaining on treatment beyond a year. Notably, responses appeared across the cohort irrespective of tumor PD-L1 expression, hinting that the combination might reach patients who historically derive little benefit from checkpoint inhibition. Disease control—tumors that shrank or remained stable—encompassed the large majority of treated patients. Whether that translates into longer survival will require longer follow-up, but the depth and persistence of the early responses is precisely what caught researchers’ attention in a disease where first-line chemotherapy shrinks tumors in only about a third of cases.

The safety profile combined the known liabilities of both drugs. Toxicities consistent with trastuzumab deruxtecan—nausea, fatigue, hair loss and myelosuppression, particularly anemia and neutropenia—were common, and roughly half of patients experienced grade 3 or worse treatment-related events that required dose interruption or reduction. Durvalumab contributed immune-mediated effects such as thyroid dysfunction and liver enzyme elevations. The toxicity demanding the most vigilance was interstitial lung disease, the inflammatory lung injury recognized as a class effect of trastuzumab deruxtecan across its development program. It occurred in only a small fraction of patients, predominantly at low grade, and was managed with treatment interruption and corticosteroids. No unexpected safety signals emerged, the investigators report, and the pattern of events matched what had been seen when each drug was used alone. Yet because durvalumab can itself provoke pneumonitis, the overlap of two lung-toxicity risks made pulmonary monitoring a central element of the protocol, with clinicians urged to suspect drug-related lung injury in any new respiratory symptom and to treat it early.

The trial was led by Peter Schmid of Queen Mary University of London, with Se Hyun Im of Asan Medical Center in Seoul and Zbigniew Nowecki of the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw among the senior investigators. Writing in Nature Cancer, the authors describe response rates that compare favorably with historical benchmarks for first-line therapy in hormone-receptor-negative, HER2-low disease, and argue that the pairing’s activity independent of PD-L1 status addresses one of immunotherapy’s persistent blind spots in this subtype. They are careful, however, to frame the study as hypothesis-generating. With a single-arm design and no randomized comparator, the results establish feasibility, response depth and tolerability, but not survival advantage. The authors call for the regimen to be advanced into randomized phase III testing, where durvalumab plus trastuzumab deruxtecan would be measured head-to-head against the current standards of pembrolizumab with chemotherapy and chemotherapy alone.

The results arrive at a moment when the logic of breast cancer sequencing is being rewritten. Trastuzumab deruxtecan is already approved for HER2-low metastatic disease, but only after patients have progressed on earlier lines of therapy; its position has been in the back half of the treatment journey. Moving the drug to the front line, and pairing it with an immunotherapy, raises immediate questions. Do patients who receive the conjugate early forfeit its later benefit if the disease eventually progresses, or does earlier exposure translate into longer survival? How should clinicians handle tumors that are HER2-ultralow, expressing the protein at even fainter levels that current tests barely register? And does the HER2-low label, which depends on subjective immunohistochemistry scoring, reliably identify the right patients when the stakes are a front-line regimen? The HER2-low population is also biologically heterogeneous, mixing immunologically inflamed tumors with cold ones, and translational analyses from BEGONIA are expected to clarify which microenvironments the combination actually reprograms.

For now, the findings stand as a proof of principle: a targeted chemotherapy payload and an immune checkpoint inhibitor can be combined safely and effectively as an initial treatment in one of breast cancer’s most difficult molecular neighborhoods. If randomized trials confirm the kind of survival gains that single-arm data cannot demonstrate, the first-line landscape for hormone-receptor-negative, HER2-low metastatic disease could shift away from cytotoxic chemotherapy toward regimens that couple precision targeting with immune activation—a strategy oncologists have pursued across solid tumors for a decade. The necessary next step—randomized confirmation—will determine whether regulators follow where the biology points. With survival in this population still measured in only a few years, and breast cancer remaining the leading cause of cancer death in women worldwide, the stakes are considerable. The BEGONIA results suggest the tools to change that arithmetic may already be in hand; what remains is to prove, in the rigorous language of randomized evidence, that the promise holds.

Triple-negative breast cancer remains one of the most challenging forms of breast malignancies due to its heterogeneity and lack of targetable receptors, such as estrogen, progesterone, or HER2. These tumors are often characterized by rapid progression, early metastasis, and poor prognosis compared to other breast cancer subtypes. Historically, chemotherapy has been the cornerstone of systemic treatment for mTNBC, yet the survival benefits have been modest. This clinical trial ventured into uncharted territory by combining carboplatin, a platinum-based cytotoxic agent known for inducing DNA cross-linking and tumor cell apoptosis, with nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor designed to unleash anti-tumor immune responses.

The scientific rationale behind integrating nivolumab with carboplatin hinges on the immunogenic cell death triggered by platinum chemotherapy. Carboplatin induces DNA damage that not only causes tumor cell death but may also increase neoantigen presentation on cancer cells, enhancing their visibility to the immune system. By blocking the PD-1 receptor on T-cells using nivolumab, the immune evasion mechanisms often exploited by cancer cells can be disrupted, potentially restoring and amplifying cytotoxic T-lymphocyte activity against tumor cells. This synergistic interplay between chemotherapy-induced immunogenicity and immune checkpoint blockade has given rise to a new frontier in combinatorial cancer regimens.

Conducted with rigorous methodology, the randomized phase II trial enrolled patients diagnosed with metastatic triple-negative breast cancer. Participants were stratified to receive either carboplatin alone or carboplatin in conjunction with nivolumab. Treatment schedules, dosing regimens, and monitoring protocols followed standardized oncology clinical trial frameworks to ensure robust and reproducible data collection. Clinical endpoints included progression-free survival, overall survival, objective response rate, and safety profile assessments, with parallel exploratory biomarker analyses aimed at elucidating the underlying immune landscape.

Preliminary results demonstrated a statistically significant improvement in progression-free survival in the cohort receiving the combination therapy relative to carboplatin monotherapy. This suggests that nivolumab’s immunomodulatory effects are efficacious in delaying disease progression in mTNBC—a noteworthy finding given historical challenges in achieving durable responses in this patient population. Furthermore, the objective response rate saw a marked increase with the addition of nivolumab, signaling enhanced tumor shrinkage and disease control.

From an immunological perspective, the study illuminated critical insights into the tumor microenvironment alterations induced by the combined regimen. Biopsies and peripheral blood analyses revealed increased infiltration of CD8+ cytotoxic T-cells in tumors from patients receiving combination therapy, alongside a decrease in immunosuppressive regulatory T-cells and myeloid-derived suppressor cells. These findings corroborate the hypothesis that carboplatin primes the tumor to be more susceptible to immune-mediated attack when the PD-1 pathway is inhibited.

Safety and tolerability data also emerged as a focal point, considering the potential for overlapping toxicities between chemotherapy and immune checkpoint inhibitors. While the addition of nivolumab was generally well-tolerated, heightened incidences of immune-related adverse events such as pneumonitis and colitis were observed, necessitating vigilant clinical management. Nonetheless, the overall safety profile aligned with expectations established in previous immuno-oncology trials, underscoring that this therapeutic combination is a feasible option in carefully selected patients.

Importantly, the trial incorporated comprehensive genomic and transcriptomic analyses to identify predictive biomarkers of response. Tumors with higher tumor mutational burden and increased expression of immune activation signatures correlated with improved outcomes upon receiving nivolumab, suggesting a precision medicine approach could optimize patient selection. This molecular stratification could spearhead future iterations of clinical protocols, tailoring immune checkpoint blockade to those most likely to benefit.

The implications of this study extend beyond the immediate clinical outcomes. By demonstrating the tangible benefits of coupling conventional cytotoxic agents with immune checkpoint inhibitors in mTNBC, the research paves the way for novel combination regimens and synergistic therapies that could be extrapolated to other challenging malignancies. Moreover, it affirms the centrality of the immune microenvironment in mediating therapeutic responses, reigniting interest in designing interventions that disrupt tumor-immune evasion networks.

While the trial offers rays of hope, it also prompts important questions about resistance mechanisms and durability of immune responses. Long-term follow-up is essential to determine whether the initial gains in progression-free and overall survival translate into persistent benefit and potential cure. The development of acquired resistance, immune escape adaptations, and the impact of prior treatments remain areas ripe for investigation.

Moreover, integrating this regimen into existing standards of care warrants careful consideration. Future phase III studies will be indispensable in confirming the efficacy and safety signals seen in this phase II trial, potentially setting new benchmarks for frontline therapy in metastatic triple-negative breast cancer. Health economics analyses and quality-of-life assessments will also be critical to assess the practicality and patient-centric aspects of incorporating immunotherapy into treatment paradigms.

From a mechanistic standpoint, the trial underscores the paradigm shift in oncology from solely targeting tumor cells to orchestrating comprehensive immunologic assaults leveraging the body’s own defenses. The combination of carboplatin and nivolumab exemplifies this approach, reflecting a synergistic docking of cytotoxic insult with immune activation. This dual strategy not only kills cancer cells directly but also educates and energizes immune effectors to sustain anti-tumor activity.

In summary, the randomized phase II trial led by Garrido-Castro, Graham, Li, and colleagues represents a major stride forward in the quest to improve outcomes for patients burdened by metastatic triple-negative breast cancer. By harnessing the interplay between platinum chemotherapy and PD-1 checkpoint inhibition, this study opens promising therapeutic avenues that harness both cellular cytotoxicity and immune reinvigoration. As the oncology field eagerly anticipates confirmatory phase III data and broader clinical adoption, the findings herald a new era of combinatorial immuno-oncology regimens transforming the future of cancer care.

Subject of Research: Metastatic Triple-Negative Breast Cancer Treatment with Carboplatin and Nivolumab Immune Checkpoint Blockade

Article Title: Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial

Article References:
Garrido-Castro, A.C., Graham, N., Li, K.X. et al. Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73085-1

Image Credits: AI Generated

HER2-negative breast cancer, characterized by the absence of human epidermal growth factor receptor 2 expression, comprises a heterogeneous group of tumors that often demonstrate less responsiveness to targeted therapies compared to their HER2-positive counterparts. The quest for innovative treatment modalities in this subgroup has intensified, particularly in the setting after neoadjuvant chemotherapy, where residual disease presents a significant prognostic challenge. The SOLTI-1503 PROMETEO study specifically addresses this clinical gap by exploring a window-of-opportunity approach, leveraging the tumor microenvironment’s immunogenic potential during a critical juncture in treatment.

Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus type 1 (HSV-1) engineered to selectively infect and lyse tumor cells while simultaneously expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) to promote a robust antitumor immune response. The mechanism of T-VEC involves direct tumor destruction as well as modulation of local and systemic immunity, transforming “cold” tumors into “hot,” immune-responsive microenvironments. This property makes it a highly attractive candidate for combination with immune checkpoint inhibitors such as atezolizumab, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1).

Atezolizumab functions by inhibiting the interaction between PD-L1 on tumor cells and PD-1 receptors on T cells, effectively reversing immune suppression and reinvigorating cytotoxic T lymphocyte activity against cancer cells. However, monotherapy with immune checkpoint inhibitors in HER2-negative breast cancer has shown limited efficacy, presumably due to the immunologically “cold” nature of many tumors within this subgroup. Therefore, the hypothesis underlying the SOLTI-1503 PROMETEO trial was that T-VEC could prime the immune system and enhance the therapeutic effect of atezolizumab.

The trial enrolled patients with HER2-negative breast cancer who had undergone neoadjuvant chemotherapy but retained residual disease, a setting indicative of less favorable outcomes and elevated risk of relapse. This window-of-opportunity design utilized the post-chemotherapy interval to administer the investigational treatments, aiming to eradicate microscopic residual disease through synergistic immuno-oncological mechanisms.

Early results from the SOLTI-1503 PROMETEO trial indicate encouraging responses, including increased infiltration of CD8+ T cells within the tumor microenvironment and heightened expression of immune activation markers. These immunological shifts correlate with improved clinical outcomes, suggesting that the combination therapy effectively alters the tumor milieu from immunosuppressive to immune-activated. Such findings underscore the potential of this therapeutic strategy to enhance long-term disease control in a patient population that otherwise faces a grim prognosis.

Furthermore, the safety profile observed in this trial reflects manageable adverse events consistent with those previously reported for T-VEC and atezolizumab, reinforcing the feasibility of this combination in clinical settings. The integration of oncolytic virotherapy with immune checkpoint blockade represents a novel and pragmatic approach to tackling residual breast cancer disease, capitalizing on distinct but complementary mechanisms of action.

This study also delves deeply into the molecular and cellular underpinnings of the synergy observed. By leveraging advanced genomic and proteomic analyses, researchers characterized changes in tumor-associated antigens and immune cell populations that inform the predictive biomarkers of response. Such insights are critical for patient stratification and optimizing personalized immunotherapy regimens in the future.

The therapeutic implications extend beyond breast cancer, as the concept of enhancing checkpoint blockade efficacy through oncolytic viruses may be broadly applicable across various malignancies exhibiting immune resistance. The SOLTI-1503 PROMETEO trial thus serves as a paradigm for integrating viro-immunotherapy into conventional oncologic care.

As this research progresses toward larger randomized studies, it holds the promise of establishing a new standard of care, particularly for patients with limited treatment options following neoadjuvant chemotherapy. The potential to convert residual disease from a harbinger of relapse into a target for immune eradication could significantly improve survival and quality of life.

In conclusion, the SOLTI-1503 PROMETEO window-of-opportunity phase II trial marks a pivotal advance in the landscape of HER2-negative breast cancer treatment. By demonstrating the potent combination of talimogene laherparepvec and atezolizumab, it exemplifies the power of immune modulation to overcome therapeutic barriers. This innovative approach heralds a new era in precision oncology, offering renewed hope for patients and clinicians alike in the fight against this formidable disease.

Subject of Research:
Breast cancer immunotherapy, specifically the combination of talimogene laherparepvec and atezolizumab in HER2-negative breast cancer patients following neoadjuvant chemotherapy.

Article Title:
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Article References:
Pascual, T., Vidal, M., Cejalvo, J.M. et al. Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). Nat Commun (2026). https://doi.org/10.1038/s41467-026-69222-5

Image Credits:
AI Generated

Central to this discovery is the tumor microenvironment—the complex and dynamic “neighborhood” surrounding cancer cells that includes various types of immune cells, stromal components, and signaling molecules. Within this milieu, tumor-associated macrophages (TAMs) emerge as critical players. These immune cells, normally involved in tissue repair and defense, are co-opted by tumors to support malignant progression. Researchers focused on a specific TAM subtype characterized by the expression of CD163 and the immune checkpoint molecule PD-L1. PD-L1 is known for its role in helping cancer cells evade immune detection, famously targeted by immune checkpoint inhibitors in various cancers.

The Sylvester team found that these PD-L1-positive TAMs accumulate in greater numbers within tumors from patients that developed resistance to tamoxifen therapy. Acting like “bodyguards” shielding the cancer from immune attack and therapy-induced death, these macrophages create an immunosuppressive niche that fosters tumor survival and regrowth. Their recruitment is orchestrated by DLL1, a signaling ligand secreted by the cancer cells themselves. DLL1 initiates a chemotactic cascade, operating through the CCR3/CCL7 pathway, to draw these macrophages into the tumor microenvironment.

This macrophage infiltration not only supports cancer cell survival but also maintains a subpopulation of cancer stem cells—an inherently resilient fraction of tumor cells capable of self-renewal and fueling tumor recurrence. Moreover, the presence of PD-L1-positive TAMs induces exhaustion of cytotoxic CD8+ T cells, the immune system’s frontline soldiers against malignancy. The combination of immune evasion and sustained cancer stem cell populations underscores the complexity and resilience of tamoxifen-resistant breast tumors.

To dissect this resistance mechanism and explore therapeutic interventions, researchers developed two preclinical models of ER+ breast cancer that mimic endocrine therapy resistance. In these models, blocking DLL1 and PD-L1 simultaneously with targeted antibodies, in conjunction with low-dose tamoxifen, led to marked reduction in tumor size. Tumor burden was further diminished by a significant decrease in cancer stem cell populations. This triple-therapy approach not only disrupted the protective macrophage niche but also reactivated the immune response by revitalizing exhausted T cells, effectively tipping the scales back against the cancer.

What sets this approach apart from previous strategies is its multipronged attack—targeting tumor cell signaling, dismantling the supportive immune microenvironment, and applying conventional hormone therapy at subtherapeutic doses to minimize side effects. The findings were validated both in preclinical models and patient-derived explant cultures, underscoring translational potential.

Of particular clinical significance, high levels of DLL1 and PD-L1+ TAMs in human tumors correlated strongly with poor patient outcomes and resistance to both tamoxifen and fulvestrant. These data suggest that quantifying these markers could aid in patient stratification and therapeutic decision-making in the future. The implication is profound: by interrupting DLL1-mediated recruitment of immunosuppressive macrophages and blocking PD-L1 checkpoint signaling, we may overcome a major hurdle in endocrine therapy resistance.

Despite the excitement, Dr. Rumela Chakrabarti, senior author and co-director of the Sylvester Surgical Breast Cancer Research Group, emphasizes cautious optimism. Extensive in vivo validation and early-phase clinical trials are necessary before this strategy can be widely implemented. Human tumors exhibit heterogeneity and complexity beyond preclinical models, requiring thorough investigation of potential side effects and resistance mechanisms to the triple therapy.

The broader scientific significance of this work lies in shifting the focus from cancer cells in isolation to the intricate ecosystem in which they thrive. Tumors are not merely rogue cell populations but communities of diverse cells interacting dynamically. Understanding and targeting these interactions—especially how malignant cells exploit immune cells to evade destruction—open new frontiers for cancer treatment.

This research also contributes to the expanding narrative of cancer immunotherapy, demonstrating how traditional hormone therapies can be synergized with immune modulation to tackle resistant tumors. Such integrated approaches may herald a new era wherein cancers previously deemed untreatable with endocrine therapy become manageable chronic conditions.

In conclusion, the identification of DLL1-responsive PD-L1+ tumor-associated macrophages as key mediators of endocrine resistance offers a compelling target for therapy. The triple combination of anti-DLL1, anti-PD-L1, and low-dose tamoxifen holds remarkable promise in preclinical settings, illuminating a path toward improved outcomes for patients suffering from stubborn ER+ breast cancer. As research progresses, this strategy could redefine standards of care, illustrating the power of dissecting the tumor microenvironment to unlock innovative, life-saving therapies.

Subject of Research: Endocrine resistance in estrogen receptor-positive (ER+) breast cancer mediated by tumor-associated macrophages.

Article Title: DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer

News Publication Date: November 5, 2025

Web References:

• Sylvester Comprehensive Cancer Center
• Science Translational Medicine Article DOI
• InventUM blog
• SylvesterCancer on X

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Breast cancer, tumor-associated macrophages, endocrine therapy resistance, estrogen receptor-positive, PD-L1, DLL1, cancer stem cells, tumor microenvironment, immune checkpoint inhibition, tamoxifen resistance, fulvestrant resistance, immunosuppression